Coronavirus disease 2019 (COVID-19) was declared a pandemic on March 11, 2020. In efforts to reduce the risk of transmission, telehealth visits for routine care has significantly increased in the United States. Cystic fibrosis patients have been categorized as a highly vulnerable population to COVID-19 infection. Cystic Fibrosis centers are rapidly assessing and responding to the pandemic to ensure the safety of CF patients. At our Cleveland Clinic Cystic Fibrosis center, we transitioned outpatient clinics to a virtual care model in March 2020. The objectives of my presentation will include 1) the pathophysiology of COVID-19 in CF and 2) the strategies that were implemented at our Cleveland Clinic CF Center for outpatient management of CFRD through telehealth during the COVID-19 crisis
Dr. Hasan received her medical degree from Ohio University Heritage College of Osteopathic Medicine in 2008. All throughout her four years of medical school, she was the recipient of Jerry A. Zinni scholarship. She continued her post graduate training at Summa, Akron City Hospital with a residency in Internal Medicine. Her interest in research and endocrinology enabled her to pursue a three-year research fellowship in Endocrinology and Metabolism at University of Nebraska Medical Center in Omaha, NE. Her research study on the effects of All-trans Retinoic acid in obesity related type 2 diabetes was well recognized, leading to early career travel awards at the 95th annual Endocrine Society meeting in 2013 as well as 74th American Diabetes Association meeting in 2014. Her academic achievements throughout her fellowship led to her appointment as a Clinical Instructor at University of Nebraska Medical Center in 2014. She was honored to present her work on All-trans Retinoic acid on weight, glucose homeostasis and white adipose tissue internationally, initially at 22nd European Congress on Obesity in Prague, Czech Republic in 2015, followed by the European Association for the Study of Diabetes 51st Annual meeting in Stockholm, Sweden, later that year. She served as co-investigator on a registry maintaining online database for complex causes of diabetes, its complications and their relationship to post transplant diabetes, hearing loss and pancreatic cancer. Dr. Hasan’s strong academic and research background led to her appointment as a Clinical Assistant Professor at Cleveland Clinic Lerner College of Medicine as well as an Associate Staff for the Endocrinology and Metabolism Institute in late, 2015. She remains an active faculty member with the Endocrinology fellowship program at Cleveland Clinic with multiple poster presentations at national society meetings. She assumed the role of the Director of the South Region with the Endocrinology and Metabolism Institute in 2019. She was subsequently awarded an EnVision grant for her role as a primary investigator in her study of optimizing glycemic control in Cystic fibrosis related diabetes.